PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 1, 2014New England Journal of Medicine3,066 citationsOpen Access

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

View Full Paper
TBTomasz M. BeerAAAndrew J. ArmstrongDRDana E. Rathkopf

Key Points

  • This research aims to assess the effectiveness of enzalutamide in delaying chemotherapy in men with metastatic prostate cancer.
  • Randomized trial design with men diagnosed with metastatic prostate cancer
  • Intervention with enzalutamide prior to chemotherapy initiation
  • ClinicalTrials.gov registration number NCT01212991.
  • Enzalutamide significantly decreased the risk of radiographic progression and death.
  • Delay in chemotherapy initiation was observed among participants receiving enzalutamide.

Abstract

Enzalutamide significantly decreased the risk of radiographic progression and death and delayed the initiation of chemotherapy in men with metastatic prostate cancer. (Funded by Medivation and Astellas Pharma; PREVAIL ClinicalTrials.gov number, NCT01212991.).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Beer et al. (2014) studied this question.

synapsesocial.com/papers/69dd258403ecda3005e52d51https://doi.org/10.1056/nejmoa1405095
Ask AI
Helpful
Bookmark
Share
View Full Paper